PT -期刊文章AU - Tran Trung n . AU -王,伊丽莎白盟——Sarkar Rajiv AU - Nan,卡桑德拉盟——罗宾侬安娜莉莎非盟-奥利里,卡洛琳盟——Muzwidzwa Ruvimbo AU -贝尔顿,劳拉盟——五胞胎,詹妮弗·k·TI -口服皮质类固醇处方模式哮喘在法国,德国,意大利,和英国的援助- 10.1183/13993003.02363 -2019 DP - 2020年1月01 TA -欧洲呼吸杂志PG - 1902363 4099 - //www.qdcxjkg.com/content/early/2020/03/04/13993003.02363 - 2019. -短4100 - //www.qdcxjkg.com/content/early/2020/03/04/13993003.02363 - 2019. -完整的AB -口服皮质类固醇(OCS)用于管理哮喘急性加重和严重、无法控制的哮喘，但OCS的使用与不良反应相关。我们的目的是描述OCS在西欧哮喘患者实际管理中的使用模式。我们使用了2011年7月至2018年2月期间法国、德国、意大利和英国数据库中的电子医疗记录。纳入年龄≥12岁、诊断为哮喘、±6个月内服用≥1种非ocs哮喘药物、入组前6个月及入组后90天的现有资料。高OCS使用定义为在随访期90天窗内OCS≥450 mg。根据OCS使用状态描述随访期间的基线特征和OCS使用情况。在702 685例哮喘患者中，14-44%为OCS使用者，6-9%为高OCS使用者。所有国家的OCS高使用率每年约为3%。 High OCS users had a mean 1–3 annual OCS prescriptions, with an average daily OCS dosage of 1.3–2.2 mg. For patients who continued to meet the high use definition, daily OCS exposure was generally stable at 5.5–7.5 mg for at least 2 years, increasing the risk of adverse effects.Our study demonstrates that OCS use is relatively common across the four studied European countries. Data from this study may provide decisive clinical insights to inform primary care physicians and specialists involved in the management of severe, uncontrolled asthma.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Tran reports personal fees from AstraZeneca, outside the submitted work.Conflict of interest: Dr. King reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Sarkar reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Nan reports personal fees from AstraZeneca, personal fees from GlaxoSmithKline, outside the submitted work.Conflict of interest: Dr. Rubino reports personal fees from Evidera, outside the submitted work.Conflict of interest: Dr. O'Leary reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Muzwidzwa reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Belton reports personal fees from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Quint reports other from Imperial College London, outside the submitted work.